Neonatal Opioid Withdrawal Syndrome
12
2
5
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 29/100
8.3%
1 terminated out of 12 trials
83.3%
-3.2% vs benchmark
33%
4 trials in Phase 3/4
60%
3 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (12)
Neurostimulation to Improve NOWS Outcomes
Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study
Target Trial Emulation for Pharmacologic Treatment of Neonatal Opioid Withdrawal Syndrome
MicroRNA Biomarkers for Neonatal Opioid Withdrawal Syndrome
Use of SVS Device to Improve Outcomes for Neonatal Opioid Withdrawal Syndrome.
Medication Treatment for Opioid Use Disorder in Expectant Mothers
Trial to Shorten Pharmacologic Treatment of Newborns With Neonatal Opioid Withdrawal Syndrome (NOWS)
ACT NOW Longitudinal Study: Outcomes of Babies With Opioid Exposure Study
Maternal Opioid Treatment: Human Experimental Research - Data Yield Appropriate Decisions
CHF6563 in Babies With Neonatal Opioid Withdrawal Syndrome
Randomized Control Trial of Buprenorphine vs. Morphine for the Treatment of Neonatal Opioid Withdrawal Syndrome (NOWS)
Optimal Morphine Dosing Schedule for Neonatal Abstinence Syndrome